Having observed increased IGF-Trap brain diffusion in a rat model, the TMS apparatus was subsequently adapted to administer rTMS to mice, in order to enable utilization of a mouse glioma model to assess the therapeutic benefit of administering IGF-Trap in conjunction with rTMS. This evidence concerns the gene IGF1 and central nervous system cancer.